Bioqual (OTCMKTS:BIOQ) Announces Earnings Results

Bioqual (OTCMKTS:BIOQ) issued its quarterly earnings results on Tuesday. The company reported ($0.84) earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $9.84 million for the quarter. Bioqual had a negative return on equity of 2.67% and a negative net margin of 2.27%.

Bioqual Stock Performance

Shares of BIOQ stock opened at $37.51 on Thursday. The company has a market capitalization of $33.38 million, a P/E ratio of -34.73 and a beta of -0.19. The business’s 50 day moving average is $37.51 and its two-hundred day moving average is $38.36. Bioqual has a 12-month low of $33.00 and a 12-month high of $60.00.

Bioqual Company Profile

Bioqual, Inc is a U.S.-based contract research organization specializing in preclinical immunology and pharmacology services for the biopharmaceutical industry. The company offers a range of in vivo and in vitro testing solutions designed to support vaccine development, immuno-oncology programs and other therapeutic modalities. Bioqual’s service portfolio encompasses assay development, safety and efficacy studies, biomarker analysis and specialized immunogenicity assessments.

Leveraging proprietary humanized animal models and nonhuman primate research platforms, Bioqual helps clients evaluate biological activity, toxicity and pharmacokinetics of investigational compounds.